Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Miplyffa, the most common co-covered peer. Justin Renz appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Miplyffa, the most common co-covered peer. Justin Renz appears in 1 tracked Biotech story from March 5, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Justin Renz. Shared-story counts are live from our verified record — not editorial picks.
Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.
Source: finanznachrichten.de · Seeking Alpha
Justin Renz is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
